For most of the last fifty years, the question about psilocybin in American medicine was whether. On Monday, September 14, 2026, the U.S. Food and Drug Administration held a public hearing that quietly assumed a different question: how.
The session, formally titled “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs,” ran from 12:30 to 4:30 p.m. Eastern at the FDA’s White Oak campus in Silver Spring, Maryland, with a live webcast. No drug was approved. No vote was taken. But for anyone following psilocybin as a treatment for depression, it was the clearest look yet at how the regulator is thinking about the day after approval.
What kind of meeting this was
This was a “Part 15” hearing — an informal, listen-only format the FDA uses when it wants broad public input on a policy question. According to the trade publication Psychedelic Alpha, it is only the third such hearing the agency has held since 2020.
Interest was high. A legal summary published on Mondaq reports more than 18,000 registrations and over 200 requests to speak, from which the FDA selected about 80 presenters. Psychedelic Alpha counted roughly 300 people in the room and about 1,000 more watching the livestream. Each speaker had around two minutes; about half appeared in person and half by video.
Listening was a panel of federal officials from the FDA and its partners: the National Institute on Drug Abuse (NIDA), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Veterans Health Administration, and the health research agency ARPA-H. Marta Sokolowska, a deputy center director at the FDA, opened the session and framed it as part of a “whole of government” effort.
What was on the table - and what wasn't
The Federal Register notice set out four topics:
- Provider training and credentialing — who is qualified to sit with a patient during a session that can last six to twelve hours.
- Patient safety — screening, monitoring, and follow-up.
- Access — insurance coverage, reimbursement, workforce, and clinic capacity.
- Data collection — how to track outcomes and harms consistently once these medicines are used outside of trials.
Just as important is what the FDA excluded. Comments on whether any specific drug is safe or effective, on controlled-substance scheduling, on legalization or decriminalization, and on ceremonial use were all out of scope. So this was not a hearing about psilocybin for depression in the strict sense. It was a hearing about the delivery system any approved psychedelic will have to live inside — and psilocybin for depression is very likely to be the first to test it.

Why psilocybin and depression sit at the center anyway
The hearing did not happen in a vacuum. In April 2026, a presidential executive order directed federal agencies to speed the research, review, and approval of psychedelic drugs for serious mental health conditions. Days later, the FDA issued three Commissioner’s National Priority Vouchers, which aim to shorten a review that normally takes ten to twelve months down to one or two. Two of the three went to psilocybin: Compass Pathways’ COMP360 for treatment-resistant depression, and the nonprofit Usona Institute’s psilocybin program for major depressive disorder. The third went to methylone for PTSD. In July, the agency finalized its guidance on how psychedelic clinical trials should be designed.
Compass is furthest along. Its two Phase 3 trials enrolled more than 1,000 people with treatment-resistant depression. The company reports that a single 25 mg dose produced a statistically significant improvement of roughly 3.6 to 3.8 points over the comparison group on a standard depression scale (the MADRS), with effects appearing as early as the next day. In six-month data released in July, 39% of participants on the 25 mg dose had a clinically meaningful response at week six and held it through week 26. These were people whose current depressive episode had lasted more than three years on average.
Those numbers deserve honest reading. A three-to-four point advantage is real but modest, and a majority of participants did not reach that response threshold. Still, for a population that has already failed multiple treatments, a rapid and durable option from one or two doses is meaningful. Compass says its rolling application is on track to be completed in the fourth quarter of 2026, with a possible launch in the first half of 2027 — if the FDA approves it and the DEA reschedules the drug.
That timeline is why Monday mattered. The rules discussed in that room could apply to a real psilocybin product within months.

Who spoke, and where they disagreed
Is the drug the treatment, or is the therapy? This was the deepest fault line. As Psychedelic Alpha reported, Lawrence Leeman of the University of New Mexico stressed psychedelic-assisted therapy, with preparation beforehand and integration afterward. Clinical psychologist Geoff Bathje argued that the therapeutic relationship is being minimized, and that cost pressure could strip it out of real-world care. On the other side, Peter Hendricks of the University of Alabama at Birmingham warned that requiring psychotherapy in every model “would fall hardest on the people least able to find care elsewhere,” and urged that requirements follow the evidence in each product’s label rather than a blanket rule.
Who gets to provide it? As Psychiatric Times reported, Rajan Dunne, MD, of Sheppard Pratt argued that good psychedelic care “requires the full scope of psychiatric expertise.” Nurse practitioner Tina Braddock countered that the licensed nursing workforce is “already here, trained, deployable now.” Veterans’ advocate Christian Reed urged against “locking this inside clinics in a handful of major cities.”
How cautious should the start be? Researcher Eddie Jacobs pointed to a meta-analysis finding serious adverse events in about 4% of trial participants with pre-existing psychiatric conditions, and argued that “it’s better to start with stronger protections and adjust them as the evidence accumulates.” Amber Barnato, MD, of Dartmouth noted that even encouraging results in seriously ill patients come from “small, functionally unblinded trials” — meaning most participants can tell whether they received the drug. Aliya Lilienstein, MD, of UC Berkeley proposed a standardized system for classifying adverse events, modeled on oncology. Former FDA official Lawrence Goldkind, MD, argued against a single class-wide safety program (known as a REMS), since these compounds differ in risk.
Access is a safety issue. Several speakers made the point that coverage is not a side question. One noted that insurers build their coverage rules from the FDA label, so what the label says about support and monitoring will determine who can afford care. Air Force veteran Lynn Watkins put it sharply, as quoted by Reuters: “Approval alone is not access. A breakthrough therapy nobody can reach is not a breakthrough — it is a press release.” Melissa Lavasani of the Psychedelic Medicine Coalition asked that important safety and treatment signals not “disappear inside population averages,” and speakers called for sex-specific data such as hormonal status and pregnancy to be tracked.
The skeptics and the grieving. Kevin Sabet of the Foundation for Drug Policy Solutions said psychedelics “should earn approval the way any other class of drug does, through science and trials, not politics.” The American Psychiatric Association said the FDA’s determination of safety and effectiveness “must remain the foundation” for any clinical use. And Susan Taymor Sagy spoke about the death of her 21-year-old daughter following psychedelic use, asking that real risk education accompany any approval. Others called for Indigenous communities to be included in rulemaking.

The outcome: silence, and an open docket
The honest answer to “what was decided?” is: nothing, by design. A Part 15 hearing gathers input; it does not produce a ruling.
One detail drew comment. Although time and microphones were set aside for it, the federal panel asked the speakers no questions at all — a contrast with earlier hearings of this type. Psychedelic Alpha’s reading is that the event was partly a demonstration of responsiveness, and that the entry of psychedelics into U.S. medicine is increasingly treated as a given. Compass Pathways, notably, did not use its scheduled speaking slot.

What this means
For people living with depression: nothing changes today. Psilocybin is not an approved medicine, and vouchers and “breakthrough” designations are not findings that a drug is safe or effective. But the conditions of future care — who sits with you, what screening you receive, what follow-up exists, and whether insurance pays — are being shaped now.
For therapists, nurses, and facilitators: the credentialing question is open, and the record is where it gets answered. Whether training is discipline-agnostic, whether psychiatrists must supervise, and whether therapy is required or optional will shape the whole workforce.
For the field: the hearing showed a community that agrees psychedelics are coming and disagrees on almost everything about how. That disagreement is healthy. Setting a strong safety floor at the start, and relaxing it as real-world evidence builds, was the closest thing to common ground.
What you can do: written comments carry the same weight as spoken ones. Anyone can submit them at Regulations.gov under docket FDA-2026-N-7542 until 11:59 p.m. Eastern on October 5, 2026.
Sources
- FDA (official YouTube channel): full video recording of the September 14, 2026 hearing
- Federal Register: hearing notice and request for comments (Docket FDA-2026-N-7542)
- FDA: hearing event page
- Psychiatric Times: “FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval”
- Psychedelic Alpha: “No Questions Asked: FDA’s Psychedelics Public Hearing”
- Mondaq: “FDA Holds Landmark Public Hearing on the Future Therapeutic Use of Psychedelic Drugs”
- Reuters via WHTC: “FDA holds public hearing on psychedelic drugs as Trump-driven push gathers pace”
- Medical Daily: hearing recap and comment deadline
- Managed Healthcare Executive: FDA priority vouchers for three psychedelic medications
- Compass Pathways: rolling review and priority voucher (April 24, 2026)
- Compass Pathways: six-month Phase 3 data (July 7, 2026)
- Psychedelic Beacon: psilocybin FDA approval tracker
